MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Telemedicine (Telepathology) Companies
NinePoint Medical
Organization & Developments: NinePoint
Parents
NinePoint Medical
Children
2010: Ninepoint Medical Seals Big Licensing Deal With Massachusetts General Hospital; 188 Patents and Patent Applications Licensed (2010)
2012: FDA clears NinePoint's OCT system (2012)
NinePoint's OCT Imaging Technology for Barrett's and Esophageal Dysplasia (2010)
NinePoint’s new suite of products is initially being developed to enable gastroenterologists and offsite pathologists to review advanced tissue images during biopsies and other therapeutic and diagnostic procedures, in real time.
NinePoint’s product development strategy is currently focused on novel devices that can significantly improve the access, diagnosis and treatment standards for gastroesophageal reflux disease (GERD) and Barrett’s esophagus
OFDI is a form of frequency domain optical coherence tomography (FD-OCT)
The company is also moving to new corporate headquarters in Cambridge, Mass.
The company’s first goal is to develop a device that enables remote pathology, or telepathology, which would facilitate immediat
The money will be used to develop innovative broad-based medical platforms for pathology devices.
The patents and patent applications will support NinePoint’s high resolution optical imaging platform, which is based on a next-generation optical coherence tomography (OCT) technology.
This capability could potentially provide physicians with immediately actionable information and eventually allow them to pursue
This convergence of access, diagnosis and treatment during one procedure is expected to improve patient experiences and outcomes
Jumps
*Key People: NinePoint
Finance & Acquisitions: NinePoint